Hematology department, Clermont-Ferrand University HospitalClermont-Ferrand, France
NA
(1547411) Minimal residual disease-guided combination of ibrutinib and venetoclax compared to FCR in untreated patients with CLL of intermediate risk : interim results of MRD kinetics in the ERADIC trial from the FILO group
Sunday, October 8, 20239:25 AM – 9:35 AM EDT
